Harry B Greenberg, MD
Gastroenterology · Palo Alto
- Medicare standing
- 2 flags on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
- California licence: Delinquent
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Greenberg’s office at (650) 493-5000 to ask if they take your plan before you enroll.
California Medical Board record
Licence G26684 · Delinquent
Licence status: Delinquent · since 1974 · expires 2024-05-31 · Columbia University College of Physicians and Surgeons.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$5,865 in 2023
| 2023 | 2 | 6 | $5,600 | $5,865 |
| 2022 | 1 | 7 | $10,500 | $15,721 |
| 2021 | 3 | 5 | $11,600 | $11,600 |
| 2020 | 2 | 5 | $12,502 | $12,780 |
| 2019 | 1 | 2 | $6,800 | $7,004 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | None | $5,600 | 1 payment
|
| GlaxoSmithKline | None | $265 | 5 payments
|
See all 6 published payments
| GlaxoSmithKline | Meals · 2023-12-02 | None | $32 |
| GlaxoSmithKline | Meals · 2023-12-02 | None | $25 |
| GlaxoSmithKline | Travel · 2023-11-09 | None | $70 |
| GlaxoSmithKline | Travel · 2023-11-09 | None | $70 |
| GlaxoSmithKline | Meals · 2023-11-09 | None | $67 |
| Pfizer | Consulting · 2023-02-13 | None | $5,600 |
See earlier years (2022, 2021, 2020, 2019)
2022: $15,721
| Pfizer | None | $15,721 | 7 payments
|
2021: $11,600
| Pfizer | None | $5,500 | 3 payments
|
| Emergent BioSolutions | None | $3,600 | 1 payment
|
| Merck Sharp & Dohme | None | $2,500 | 1 payment
|
2020: $12,780
| Pfizer | None | $11,928 | 4 payments
|
| Sanofi Pasteur | None | $852 | 1 payment
|
2019: $7,004
| Pfizer | None | $7,004 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (Together-Pso) · 2024 | This clinician | $2,282 |
Professional record
- NPI
- 1689731200
- Licence
- CA G26684California G26684: Delinquent · expires 2024-05-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 1330 University Ave, Palo Alto, CA, 94301
- NPI first listed
- 2007-01-02
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.